Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human ...

The positive CHMP opinion is supported by data from the pivotal LINKER-MM1 trial, which evaluated linvoseltamab in adults with R/R MM. Earlier this month, the FDA accepted for review the Biologics ...

A couple facing a terminal multiple myeloma diagnosis finds renewed hope through innovative immunotherapy, transforming blood ...

Sarclisa approved in Japan for patients with newly diagnosed multiple myeloma Approval offers access to new treatment ... predict and generally beyond the control of Sanofi, that could cause actual ...

Sarclisa approved in Japan for patients with newly diagnosed multiple myeloma Approval offers access to new treatment options for newly diagnosed ...

From uncertainty to hope for the future, they offer advice on getting through some of the toughest years of their lives ...

In a Community Case Forum in partnership with the North Carolina Oncology Association, Cristina Gasparetto, MD, discussed the CEPHEUS, IMROZ, and BENEFIT trials of treatment for transplant-ineligible ...

Medically reviewed by Marla Anderson, MD Multiple myeloma is a rare type of blood cancer that starts in your plasma cells.

Films like Strong: Living with Multiple Myeloma are essential. Multiple Myeloma is not exactly high on the list of diseases ...

Philadelphia Eagles stars carried away by their stunning Super Bowl victory prompted several apologies from American news anchors during their championship parade on Sunday. The Eagles thrashed ...

The FDA accepted Regeneron’s BLA resubmission for linvoseltamab in relapsed or refractory multiple myeloma, with a decision expected by July 10, 2025.

Instead, multiple myeloma develops due to genetic mutations (changes) in the DNA of plasma cells. What causes these genetic mutations is not fully understood, but a combination of environmental ...